Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Time to Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY) gapped down prior to trading on Monday . The stock had previously closed at $11.84, but opened at $11.18. Sysmex shares last traded at $11.61, with a volume of 880 shares traded.

Wall Street Analysts Forecast Growth

Separately, Zacks Research downgraded shares of Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Sysmex Price Performance

The stock has a market capitalization of $7.30 billion, a P/E ratio of 27.62 and a beta of 1.05. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.46 and a current ratio of 3.26. The business has a fifty day simple moving average of $9.69 and a 200-day simple moving average of $9.16.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings data on Friday, August 7th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.02. Sysmex had a net margin of 7.62% and a return on equity of 7.87%. The company had revenue of $825.85 million during the quarter, compared to analyst estimates of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. Sell-side analysts expect that Sysmex Corporation ADR will post 0.38 earnings per share for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.